
Kirsty Le Doare,1,2,3 Megan O’Driscoll,1 Kim Turner,1 Farah Seedat,1 Neal J. Russell,1 Anna C. Seale,4,5 Paul T. Heath,1 Joy E. Lawn,1 Carol J. Baker,5 Linda Bartlett,6,7 Claire Cutland,1 Michael G. Gravett,1,8,9 Margaret Ip,8,10 Shabir A. Madhi,11,12,13 Craig E. Rubens,12,14 Samir K. Saha,15 Stephanie Schrag,16 Ajoke Sobanjo-ter Meulen,17,18 Johan Vekemans,19 and Beate Kampmann20; for the GBS Intrapartum Antibiotic Investigator Group

1Centre for International Child Health, Imperial College London, United Kingdom; 2Medical Research Council Unit, Fajara, The Gambia; 3Vaccine Institute, Institute for Infection and Immunity, St George’s Hospital, University of London and St George’s University Hospitals NHS Foundation Trust, United Kingdom; 4Global Medicine, University of Southern California, Los Angeles; 5University of Warwick Medical School, Gibbet Hill, Coventry; 6Maternal, Adolescent, Reproductive and Child Health Centre, London School of Hygiene & Tropical Medicine, United Kingdom; 7King’s College London, United Kingdom; 8College of Health and Medical Sciences, Haramaya University, Dire Dawa, Ethiopia; 9Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas; 10Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 11Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa; 12Global Alliance to Prevent Prematurity and Stillbirth, Seattle, Washington; 13Department of Obstetrics and Gynecology, University of Washington, Seattle; 14Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong; 15National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; 16Department of Global Health, University of Washington, Seattle; 17Bangladesh Institute of Child Health, Dhaka; 18National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; 19Bill & Melinda Gates Foundation, Seattle, Washington; and 20World Health Organization, Geneva, Switzerland

Background. Intrapartum antibiotic chemoprophylaxis (IAP) prevents most early-onset group B streptococcal (GBS) disease. However, there is no description of how IAP is used around the world. This article is the sixth in a series estimating the burden of GBS disease. Here we aimed to review GBS screening policies and IAP implementation worldwide.

Methods. We identified data through (1) systematic literature reviews (PubMed/Medline, Embase, Literature in the Health Sciences in Latin America and the Caribbean [LILACS], World Health Organization library database [WHOLIS], and Scopus) and unpublished data from professional societies and (2) an online survey and searches of policies from medical societies and professional associations. We included data on whether an IAP policy was in use, and if so whether it was based on microbiological or clinical risk factors and how these were applied, as well as the estimated coverage (percentage of women receiving IAP where indicated).

Results. We received policy information from 95 of 195 (49%) countries. Of these, 60 of 95 (63%) had an IAP policy; 35 of 60 (58%) used microbiological screening, 25 of 60 (42%) used clinical risk factors. Two of 15 (13%) low-income, 4 of 16 (25%) lower-middle-income, 14 of 20 (70%) upper-middle-income, and 40 of 44 (91%) high-income countries had any IAP policy. The remaining 35 of 95 (37%) had no national policy (25/33 from low-income and lower-middle-income countries). Coverage varied considerably; for microbiological screening, median coverage was 80% (range, 20%–95%); for clinical risk factor–based screening, coverage was 29% (range, 10%–50%). Although there were differences in the microbiological screening methods employed, the individual clinical risk factors used were similar.

Conclusions. There is considerable heterogeneity in IAP screening policies and coverage worldwide. Alternative global strategies, such as maternal vaccination, are needed to enhance the scope of global prevention of GBS disease.

Keywords. group B Streptococcus; intrapartum antibiotic chemoprophylaxis.

Intrapartum Antibiotic Chemoprophylaxis for GBS • CID 2017:65 (Suppl 2) • S143

Group B Streptococcus (GBS; Streptococcus agalactiae) is a leading cause of early-onset disease in infants (EOGBS), defined as disease occurring on days 0–6 after birth [1]. Colonization of the maternal genitourinary or gastrointestinal tract [2] is a prerequisite for EOGBS disease [3, 4], with vertical transmission of GBS to babies occurring at or just before birth. The administration of intrapartum antibiotics aims to prevent EOGBS and is traditionally targeted based on known GBS colonization and/or the presence of peripartum clinical risk factors [4]. The potential mechanisms for prevention of EOGBS include reduction or suppression of maternal vaginal GBS colonization and thereby reduction of vertical transmission [5]. In addition, intrapartum antibiotic chemoprophylaxis (IAP) may allow the early treatment of GBS chorioamnionitis or fetal infection [6].

IAP has been recommended in the United States by the Centers for Disease Control and Prevention, American College of Obstetrics and Gynecologists, American Academy of Pediatrics, American Society for Microbiology, and American College of Nurse-Midwives since the early 1990s, with the first consensus policy in 1996 [7]. Initially, the United States recommended both risk-based and microbiological screening. However, a large multicenter cohort study in 2002 [8] found microbiological screening
to be superior in this setting. Subsequently, policy was changed to recommend microbiologic screening (using a rectovaginal swab) for GBS colonization at 35–37 weeks’ gestation or among women with threatened preterm delivery and unknown colonization status, and administration of high-dose intravenous benzylpenicillin or ampicillin in labor among those GBS colonized [4, 9]. Additionally, women with GBS bacteriuria or a previous infant with GBS disease as well as women with unknown colonization status and intrapartum risk factors such as prolonged rupture of membranes or maternal fever, are offered IAP in labor. A significant reduction in the incidence of EOGBS has been reported since the introduction of IAP policies [4, 9]; EOGBS disease in the United States declined from 1.7 per 1000 live births in the 1990s to 0.21 per 1000 live births in 2015 [10]. However, a recent Cochrane review found that although IAP may reduce the incidence of EOGBS, it did not result in a significant reduction in the mortality associated with EOGBS [11]. The review was critical of the quality of the studies included and considered there to be a high risk of bias in their methodology and execution.

Other countries such as the United Kingdom and the Netherlands have introduced IAP policies based on the presence of clinical risk factors. Risk factors used include preterm labor (<37 weeks) or premature or prolonged preterm rupture of membranes, GBS bacteriuria, previous infant with GBS disease, and maternal pyrexia (temperature >38°C) [12–14]. The use of clinical risk factor–based IAP strategies rather than microbiological screening is based on the assessment that the introduction of routine microbiological screening may be not cost-effective and that clinical risk factor–based IAP may result in fewer women being exposed to the potential risks associated with widespread antibiotic use [14, 15]. There is currently no international consensus as to whether IAP is best achieved through microbiological screening or based on the presence of clinical risk factors. There is evidence from the United States that the incidence of EOGBS has declined since the introduction of clinical screening strategies, although a larger proportion of women are treated with IAP using clinical as opposed to risk-based strategies [8]. Any consensus regarding IAP strategies should take potentially opposing points into consideration. This review is part of a supplement estimating the burden of GBS disease in pregnant women, stillbirths, and infants; To assess these data for input into estimating the global burden of GBS in pregnancy, stillbirth, and infants; 3. To summarize the data gaps to inform future strategies for the prevention of GBS disease, including maternal vaccination, globally.

METHODS

This article is part of a protocol entitled “Systematic estimates of the global burden of Group B Streptococcus in pregnant women, stillbirths and infants,” which was submitted for ethical approval to the London School of Hygiene & Tropical Medicine (reference number 11966) and approved on 30 November 2016.

Data Searches and Inputs

We identified data through 2 sources: (1) systematic review of the published literature and (2) reviews of online policies and an online survey submitted to clinicians, researchers, and relevant professionals worldwide.

Literature Searches

We undertook systematic literature searches of Medline, Embase, Literature in the Health Sciences in Latin America and the Caribbean (LILACS), Scopus, and the World Health Organization library database (WHOLIS). The literature search was updated on 20 January 2017. We used the search terms “antibiotics,” “intrapartum,” “group B Streptococcus,” and “colonization” with no date or language restrictions (full search terms are listed in Supplementary Table 1). We additionally searched the China Academic Journals Full-Text Database (with a time restriction of 3 years), and a Russian online database (Cyberleninka) with no date restrictions, as these data are often not present on classical database searches. We abstracted the data from articles in foreign languages alongside translators where available and used automatic translation if native speakers were unavailable.

Reviews of Online Policies and an Online Survey

We searched for online policies of all 130 countries listed on the International Federation of Gynecology and Obstetrics (FIGO) website [26] to identify the latest policies. In addition, we designed an online survey (Supplementary Materials 2) and approached the World Health Organization (WHO) Safer Childbirth Group, FIGO, the Royal College of Obstetricians and Gynaecologists, and the European Society for Paediatric Infectious Diseases to disseminate to their members.

Inclusion and Exclusion Criteria

Two authors (K. L. D. and K. T.) independently abstracted data onto standard Excel data entry forms. Policies were reviewed...
Intrapartum Antibiotic Chemoprophylaxis for Group B Streptococcal (GBS) Disease, as described by Lawn et al [16].

Figure 1. Intrapartum antibiotic chemoprophylaxis in disease schema for group B streptococcal (GBS) disease, as described by Lawn et al [16].

RESULTS

Study Selection

We identified 853 articles, of which we retained 60 after title and abstract screening for review of full texts (Figure 2). We excluded a further 15 articles after full-text review as these either presented duplicate data (n = 7), did not have policy data in the main text (n = 3), or did not make full text available (n = 5), leaving 45 articles for inclusion in the analysis. Of these, details of policy were already available from 30 national policy documents, leaving 15 articles containing additional policy information.

Using the international list of obstetric and gynecological societies listed on the FIGO website, we identified online policy documents from 42 countries and received responses that there was no national policy from 19 countries through FIGO. Of the remaining 71 countries, either there was no society website or no working email address, or the contacts did not reply to the FIGO email, despite receiving a read-receipt.

We received responses from 265 participants to our survey (Figure 2). We excluded 238 due to duplicate entries with identical responses from participants in the same country (n = 142), incomplete responses (n = 32), or because policy documents had already been received from the country’s obstetric association and survey responses matched the country policy (n = 72), leaving 19 unique survey responses. Details are reported in...
Supplementary Table 3. The final dataset included policies from 95 countries (FIGO = 61; original articles = 15; survey = 19)

**Intrapartum Antibiotic Chemoprophylaxis Policy and Implementation Strategies**

Sixty of 95 countries had a national IAP policy. The strategies used varied: 25 of 60 (42%) used a risk factor–based approach and 35 of 60 (58%) used both microbiological screening and risk factor approaches. Thirty-five of 95 (37%) countries had no national policy. Within these, there were reports of policies from hospitals or localities in 9 countries. Of these, 5 of 35 used rapid screening at point of labor only and 4 of 35 used risk factor approaches. Figure 3 shows countries where IAP policies were identified and Figure 4 shows IAP policy type globally.

**Intrapartum Antibiotic Chemoprophylaxis Policy by Region and Income Status**

We received responses concerning IAP policy from all regions. All developed region countries had an IAP policy (34/34). Other regions varied with the majority of countries in sub-Saharan Africa (3/20) and East Asia (1/3) reporting no IAP policy (Table 1).
The majority of countries reporting no policy came from low and lower-middle–income countries (25/33 [76%]). Two countries had limited IAP strategies, reported as risk-based screening in hospitals run by the charitable organization Médecins sans Frontières. Of countries reporting any IAP policy, 4 of 16 (25%) were from lower-middle–income countries (all risk-based screening policies). In upper-middle–income countries, 8 of 20 reported microbiological policy and 6 of 20 risk-based policy, whereas in high-income countries, 24 of 44 had microbiological and 16 of 44 risk-based policies. (Supplementary Table 3).

For countries with an IAP policy, implementation varied both within and between countries. Implementation was more frequently reported as high in countries with microbiological screening (median, 80% [range, 20%–95%]) compared to countries with clinical risk factor–based approaches (29% [range, 10%–50%]). Policy documents estimating implementation varied from estimates based on clinician reporting, especially in countries using clinical risk factor–based approaches, where clinician reporting was lower than that reported in policy documents.

Microbiological Screening for Intrapartum Antibiotic Chemoprophylaxis Administration

In 35 countries reporting microbiological screening (30 national screening, 5 hospital-level screening), women were usually screened at 35–37 weeks’ gestation. Two countries (Bulgaria and Japan) offered additional microbiological screening at 20 weeks’ gestation. In 5 countries (Poland, Bangladesh, Iran, Thailand, and Trinidad and Tobago), individual hospitals offered point-of-care screening using polymerase chain reaction when women presented in labor, in addition to screening at 35–37 weeks’ gestation. The estimated coverage of these guidelines varied greatly and ranged from 20% in Brazil to 89% in the United States and Belgium (median, 80%). Where microbiological screening methods were reported (n = 35), 21 reported sampling both the rectum and vagina either with separate (n = 2) or combined (n = 19) swabs, and 14 used only vaginal swabs.
Clinical Risk Factors for Intrapartum Antibiotic Chemoprophylaxis Administration

Twenty-five countries reported IAP based on clinical risk factors (14 national, 11 regional/hospital). There was little variation in risk factors used to determine the need for IAP. All recommended IAP use if a previous infant had GBS disease; the majority (23/25) also recommended IAP for preterm prolonged rupture of membranes, premature rupture of membranes >18 hours (PROM), or maternal GBS bacteriuria. The clinical risk factors are listed in Table 2.

Two middle-income countries reported IAP administration based on clinical risk factors (Kenya and South Africa). However, responses from the online survey suggest that coverage of this policy in these countries was low.

Clinician Responses to Survey Compared to National Policy

There was considerable variation in the survey responses between countries concerning the question “Does your country have a national policy for intrapartum antibiotics to prevent neonatal group B streptococcal disease?” In countries with risk-based screening policies, one-third of respondents answered “no,” although their obstetric societies have published national guidance. There was no discrepancy in countries reporting microbiological screening approaches.

Table 2. Clinical Risk Factors Used as a Basis for Antibiotic Administration to Reduce Group B Streptococcal Disease at Delivery

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>No. of Countries Reporting (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous infant with GBS</td>
<td>25</td>
</tr>
<tr>
<td>GBS in urine</td>
<td>23</td>
</tr>
<tr>
<td>PROM &gt;18 h</td>
<td>23</td>
</tr>
<tr>
<td>PROM &gt;24 h</td>
<td>2</td>
</tr>
<tr>
<td>Premature labor</td>
<td>23</td>
</tr>
<tr>
<td>Maternal fever</td>
<td>20</td>
</tr>
<tr>
<td>Chorioamnionitis</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 1. Intrapartum Antibiotic Chemoprophylaxis by Region and Income Status

<table>
<thead>
<tr>
<th>Region</th>
<th>Responses</th>
<th>IAP Policy</th>
<th>Microbiological Risk Factor Based</th>
<th>No Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developed regions</td>
<td>34</td>
<td>34</td>
<td>22</td>
<td>12</td>
</tr>
<tr>
<td>East Asia</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Latin America</td>
<td>12</td>
<td>9</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>North Africa</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Southeast Asia</td>
<td>7</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>South Asia</td>
<td>7</td>
<td>4</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>20</td>
<td>3</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>West Asia</td>
<td>9</td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

Antibiotics Administered

The majority of policies (50/60) recommended intravenous penicillin-based antibiotics (38/50 penicillin, 12/50 ampicillin) and clindamycin in cases of confirmed penicillin allergy. Six countries recommended a cephalosporin rather than penicillin and 4 countries in South America and 2 in Asia recommended additional vancomycin because of concerns about a theoretical risk of developing antibiotic resistance in their populations in patients with penicillin allergy.

Effect of Screening Policy on EOGBS Incidence in Countries Reporting Both National Policy and National EOGBS Incidence

EOGBS incidence data were available for 32 countries: 12 reporting a microbiological and risk-based strategy, 15 reporting a clinical risk factor strategy, and 5 reporting no national policy. The results are presented in Figure 5. Broadly, EOGBS incidence was lower in countries with a microbiological and clinical risk-based policy [1].

DISCUSSION

This review of IAP policies to prevent EOGBS disease represents the first systematic review and survey of GBS screening policies to date, with data from 95 countries of the 195 United Nations member states. It clearly demonstrates that IAP policy, strategy, and implementation are heterogeneous and different disease burden estimates and healthcare systems have led to a range of IAP approaches. This may imply that opportunities for prevention of EOGBS are being missed in some settings.

Whereas the WHO advocates screening for GBS during pregnancy, it also recognizes that screening for all pregnant women—especially in settings with known low maternal colonization prevalence, low-resource countries, and/or countries where provision of care is limited—is difficult to implement. The WHO therefore recommends that IAP should be implemented...
within the context of local policy and guidance on screening for GBS colonization [27]. In our study, low- and middle-income countries more frequently reported having no IAP policy as compared to high-income countries. There were exceptions to this; for example, both Kenya and South Africa had national IAP policies, although the survey suggested that implementation and coverage were low. In countries where access to skilled care is limited, or where the majority of births occur at home (eg, in some low-income countries where up to 80% of births are at home), implementation of IAP will always pose a challenge.

Other concerns relate to the acceptability of screening by women in high-income countries, especially the use of vaginal and rectal swabs and increased interventions during pregnancy that will limit the implementation of any IAP strategy.

It is estimated that >40% of women in the United States now receive antibiotics in labor, either for the prevention of EOGBS disease or to prevent postpartum infections following cesarean delivery [28]. Such widespread use of antibiotics in pregnancy has been raised as a concern, both in terms of potential impact on antimicrobial resistance and on possible long-term consequences in infants exposed in utero or around the time of birth. For example, an increase in infections due to Escherichia coli, especially in preterm infants, was demonstrated, following widespread IAP use in the United States [29, 30]. However, despite almost 20 years of IAP use, there is no evidence for this in large epidemiological studies in the United States [31]. Other issues include maternal anaphylaxis to β-lactams [32]. More theoretical concerns include the effect of maternal antibiotic use on the maternal and infant gut and skin flora, on the neonatal microbiome, and on subsequent immunological priming [33]. Alterations in the neonatal intestinal microbiome have been associated with increased rates of allergy, asthma, and obesity [34]. This is an area that requires further investigation in countries that offer IAP.

A maternal GBS vaccine may be the ideal solution to help reduce the burden of neonatal GBS disease in all settings. Implementation of a vaccine is likely to be higher than successful administration of IAP, especially in low- and middle-income settings and will protect against at least 75% of EOGBS. However, in some high-income settings, it may be feasible to combine with IAP when vaccination might be unavailable or suboptimal [35].

Our study also provides important additional information on national policies through its searches outside of scientific literature. However, responses from individual clinicians may not necessarily be representative of the different levels of healthcare and of health facilities that exist within a country, and we acknowledge the limitations to this approach. In high-income contexts, countries using both microbiological and clinical risk factor–based approaches for IAP had low reported EOGBS incidence [1]. We cannot assume causality, however, as this finding may reflect other differences in healthcare such as access to care.

We were also unable to correlate reported EOGBS incidence with the introduction of IAP policy in all of these countries, as policy may have been put into place after EOGBS data were collected. The reliability of data on implementation coverage of policies are hard to verify, and we have therefore categorized them using very broad thresholds (< 50% or >50%). This is important in terms of understanding the burden of disease; the category influences the risk of EOGBS disease [2] at an individual level, and is thus important in terms of a compartmental approach to modeling disease burden [16].

In conclusion, local, national, and international policies should be informed by the strongest evidence for the prevention of EOGBS and might require tailored solutions to succeed. Future GBS vaccines may offer the best opportunity to prevent EOGBS in any setting, with better implementation than policies for IAP currently in use (Table 3).

### Supplementary Data

Supplementary materials are available at *Clinical Infections Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

### Notes

**Author contributions.** The concept of the estimates and the technical oversight of the series were led by J. E. L. and A. C. S. The reviews, analyses, and first draft of the manuscript were undertaken by K. L. D. with K. T., F. S., M. O., B. K., A. C. S., J. E. L., and P. T. H. Survey design was undertaken by K. L. D. and K. T. The GBS Estimates Expert Advisory Group (C. J. B., L. B., C. M. O., B. K., A. C. S., J. E. L., and P. T. H.) contributed to the conceptual process throughout, notably on the disease schema and data inputs. The IAP investigator group (Angela Ramoni, Rikke Bek Helmg, Kaarin Makikallio, Tengiz Asatinai, Menachem Fisher, Michael Feinstein, Oz Yuval, Matan Elami Suzin, Vered Eisenberg, Alberto Berardi, Indi Trehan,
Georgia Leigh Macad, Miha Lucovnik, Claire Nkiruka Oluwalana, Pippa Letchworth, Martin Jagoutz-Herzlinger, Francis Githae Muriithi, Kouther Issa Yassen, Gerard Visser, Johan Vos, and Sophie Cooper) input data for the analyses. All the authors reviewed and gave input to the manuscript.

**Acknowledgments.** We thank Jane Plumb, Group B Strept Support, Dr Tejshri Shah, Médecins sans Frontières (MSF), and Anne Cugier, MSF, for helping with the dissemination of the survey; Claudia da Silva for administrative assistance; and Alegria Perez for coordinating author signatures.

**GBS Intrapartum Antibiotic Investigator Group.** Dr Angela Ramoni (Universitätsklinik, Innsbruck, Austria), Dr Rikke Bek Helmig (Department of Obstetrics and Gynaecology, Aarhus University Hospital, Skejby, Denmark), Dr Kaarin Makikallio (Department of Obstetrics and Gynaecology, Turku University Hospital, Finland), Prof. Tenzig Asatiani (President of Georgian Obstetricians and Gynaecologists Association, State Medical University, Georgia), Dr Menachem Fisher (Bar-Ilan University, Faculty of Medicine, Zefat, Israel), Dr Michael Feinstein (Kaplan Hospital, Rechovot, Israel), Dr Yuval Oz (Israel), Dr Matan Elami Sznit (Hadassah Hebrew University Medical Centre, Jerusalem, Israel), Dr Vered Eisenberg (MHA Sheba Medical Centre, Tel Hashomer and Sacker Faculty of Medicine, Tel Aviv, Israel), Dr Alberto Barardi (Unità Operativa di Terapia Intensiva Neonatale, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy), Dr Indi Trehan (Partners In Health, Liberia, Washington University, St Louis, Missouri; University of Malawi), Mrs. Georgia Leigh Macad (CPM (Certified Professional Midwife) Director and Founder of Abundant Grace of God Maternity Center, Tabuk City, Kalinga Philippines), Assoc. Prof. Miha Lucovnik (Department of Perinatology, Division of Obstetrics and Gynaecology, University Medical Centre, Ljubljana, Slovenia), Dr Claire Nkiruka Oluwalana (MRC Unit, The Gambia), Dr. Pippa Letchworth (Chelsea and Westminster Hospital, London, UK), Dr. Martin Jagoutz-Herzlinger (practitioner, Austria), Dr. Francis Githae Muriithi (Centre for Maternal and Newborn Health, Liverpool School of Tropical Medicine, Liverpool, UK), Dr. Kouver Issa Yassen (Practitioner, Miasan, Iraq), Prof. Gerard Visser (President International Federation of Obstetrics and Gynaecology, Geneva, Switzerland), Ms. Sophie Cooper (Royal College of Obstetrics and Gynaecology, London, UK).

**Disclaimer.** The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of any of the agencies or organizations listed.

**Financial support.** This supplement was supported by a grant to the London School of Hygiene & Tropical Medicine from the Bill & Melinda Gates Foundation (reference number OPP1131158).

**Supplement sponsorship.** This article appears as part of the supplement “The Burden of Group B Streptococcus Worldwide for Pregnant Women, Stillbirths, and Children,” sponsored by the Bill & Melinda Gates Foundation and coordinated by the London School of Hygiene & Tropical Medicine.

**Potential conflicts of interest.** Many contributors to this supplement have received funding for their research from foundations, especially the Bill & Melinda Gates Foundation, and several from Wellcome Trust, Medical Research Council UK, the Thrasher Foundation, the Meningitis Research Foundation, and one individual from the US National Institutes of Health. Members of the Expert Advisory Group received reimbursement for travel expenses to attend working meetings related to this series. A. S.-t. M. works for the Bill & Melinda Gates Foundation. A. B. attended a Pfizer Advisory Board meeting in Paris, 2015; received consultancy funding from Putnam Associates; received a consultancy fee from GSK for a conference interview; and collaborated in the Devani Project funded by the European Union. B. K. has participated in board meetings as scientific advisor for GSK and Pfizer on the subject of maternal immunization. C. J. B. has served as a member of the Presidential Advisory Committee for Seqirus Inc and of the CureVac Inc Scientific Advisory Committee, as well as undertaken consultancy work for Pfizer Inc. C. C. has received institutional compensation from Novartis for conducting GBS studies. P. T. H. has been a consultant to Novartis and Pfizer on GBS vaccines but received no funding for these activities. M. I. has undertaken sponsored research from Pfizer on pneumococcal disease in adults and from Belpharma Eumedica (Belgium) on tencoccin antimicrobial susceptibility in Enterobacteriaceae. K. L. D. has received funding by the Bill & Melinda Gates Foundation to work on research on GBS serocorrelates of protection to inform vaccine trials, and travel expenses from Pfizer to attend a meeting on an investigator-led project on GBS. S. A. M. has collaborated on GBS grants funded by GlaxoSmithKline and by Pfizer and received personal fees for being member of its advisory committee; he has also collaborated on a GBS grant funded by Minervax. All other authors report no potential conflicts of interest. All authors have submitted the ICMEJ Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**


